The Longitudinal Clinical and Genetic Study of Parkinson's Disease (LONG-PD Study)
Aims: The clinical and genetic factors that influence motor and non-motor severity, progression and outcomes in Parkinson’s disease are unknown. Identification of these factors may allow us to individualize the care of patients and improve neurological health. The Genetic Epidemiology of Parkinson’s Disease (GEO- PD) consortium clinics care for thousands of patients each year. The purpose of this study is to develop a Web-based platform for the capture and sharing of standardized data that measure motor and non-motor severity, progression and outcomes in Parkinson’s disease across 25 global sites—from 18 countries, 5 continents, 4200 cases. These patients will be followed for 15 years for collaborative research studies. Additionally, DNA will be shared in a central repository to conduct genomic studies of severity, progression and outcomes in Parkinson's disease.
Principal Investigator: Aikaterini Markopoulou, MD, PhD
IRB Approval Number: EH15-283
Funding Source: NorthShore University HealthSystem
Contact: Call 847.503.4319 with questions regarding the study
Open to enrollment: Yes

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
Aims: The purpose of this study is to determine whether the study drug, APL-130277, is effective, safe and well-tolerated in patients with Parkinson’s disease who have “OFF” episodes. APL-130277 is a fast-acting thin film formulation of apomorphine that is placed under the tongue (sublingual) and is intended to be an alternative to the injectable form of apomorphine.
Principal Investigator: Aikaterini Markopoulou, MD, PhD
IRB Approval Number: EH15-170
Contact: Please call 847.503.4322 with questions regarding the study
Open to enrollment: Yes